Immunologic Effects of Cimetidine: Potential Uses

被引:14
作者
Mavligit, Giora M. [1 ]
机构
[1] MD Anderson Hosp & Tumor Inst, Dept Clin Immunol & Biol Therapy, Houston, TX 77030 USA
来源
PHARMACOTHERAPY | 1987年 / 7卷 / 06期
关键词
D O I
10.1002/j.1875-9114.1987.tb03536.x
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Suppressor T lymphocytes play a major regulatory role in the function of the immune system. Since the discovery of histamine (H-2) receptors on the surface of these immune cells, studies have demonstrated that cimetidine diminishes the effect of suppressor T cells in both cellular-and humoral-mediated (antibody) immune reactions. Preliminary clinical results demonstrate that cimetidine has a beneficial effect on a variety of immune functions. An antineoplastic effect among tumor-bearing animals has also been found, suggesting the drug may be effective against certain human cancers, probably as an immune potentiator. Cimetidine has been used in the treatment of human cancer in combination with interferon or coumarin and as a single agent. Modest tumor response rates have been observed. The finding that cimetidine accelerates healing of herpesvirus infections is intriguing. These encouraging, albeit preliminary, results emphasize the need for additional studies on the drug's antiviral properties. (Pharmacotherapy 1987;7 (6 Pt 2):120S-124S)
引用
收藏
页码:120 / 124
页数:5
相关论文
共 29 条
[1]
AVELLA J, 1978, LANCET, V1, P624
[2]
HISTAMINE RECEPTOR-BEARING LYMPHOCYTE-T IN PATIENTS WITH ALLERGY, AUTO-IMMUNE DISEASE, OR RECURRENT INFECTION [J].
DECOCK, W ;
DECREE, J ;
VERHAEGEN, H .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1978, 11 (01) :1-5
[3]
CHARACTERISTICS AND MECHANISMS OF ACTION OF THE CONCANAVALIN A-ACTIVATED SUPPRESSOR CELL IN MAN [J].
FINEMAN, SM ;
MUDAWWAR, FB ;
GEHA, RS .
CELLULAR IMMUNOLOGY, 1979, 45 (01) :120-132
[4]
METASTATIC MALIGNANT-MELANOMA - REGRESSION INDUCED BY COMBINED TREATMENT WITH INTERFERON [HUIFN-ALPHA(LE)] AND CIMETIDINE [J].
FLODGREN, P ;
BORGSTROM, S ;
JONSSON, PE ;
LINDSTROM, C ;
SJOGREN, HO .
INTERNATIONAL JOURNAL OF CANCER, 1983, 32 (06) :657-665
[5]
GIFFORD RRM, 1981, LANCET, V1, P638
[6]
CIMETIDINE-INDUCED AUGMENTATION OF HUMAN-LYMPHOCYTE BLASTOGENESIS BY MITOGEN, BACTERIAL-ANTIGEN, AND ALLOANTIGEN [J].
GIFFORD, RRM ;
HATFIELD, SM ;
SCHMIDTKE, JR .
TRANSPLANTATION, 1980, 29 (02) :143-148
[7]
CIMETIDINE AS AN IMMUNOMODULATOR - CHRONIC MUCOCUTANEOUS CANDIDIASIS AS A MODEL [J].
JORIZZO, JL ;
SAMS, WM ;
JEGASOTHY, BV ;
OLANSKY, AJ .
ANNALS OF INTERNAL MEDICINE, 1980, 92 (02) :192-195
[8]
CIMETIDINE THERAPY OF HERPES-SIMPLEX VIRUS-INFECTIONS IN IMMUNOCOMPROMISED PATIENTS [J].
KURZROCK, R ;
AUBER, M ;
MAVLIGIT, GM .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1987, 12 (05) :326-331
[9]
HIGH-DOSE RECOMBINANT INTERLEUKIN-2 IN THE TREATMENT OF PATIENTS WITH DISSEMINATED CANCER - RESPONSES, TREATMENT-RELATED MORBIDITY, AND HISTOLOGIC-FINDINGS [J].
LOTZE, MT ;
CHANG, AE ;
SEIPP, CA ;
SIMPSON, C ;
VETTO, JT ;
ROSENBERG, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (22) :3117-3124
[10]
MARSHALL M E, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P136